174 related articles for article (PubMed ID: 35973737)
1. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab.
Kristeleit R; Mathews C; Redondo A; Boklage S; Hanlon J; Im E; Brown J
Int J Gynecol Cancer; 2022 Aug; 32(10):1250-7. PubMed ID: 35973737
[TBL] [Abstract][Full Text] [Related]
2. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract][Full Text] [Related]
3. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
JAMA Oncol; 2020 Nov; 6(11):1766-1772. PubMed ID: 33001143
[TBL] [Abstract][Full Text] [Related]
4. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm.
Goulden S; Shen Q; Coleman RL; Mathews C; Hunger M; Pahwa A; Schade R
J Health Econ Outcomes Res; 2023; 10(2):53-61. PubMed ID: 37701519
[No Abstract] [Full Text] [Related]
5. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England.
Goulden S; Heffernan K; Sen Nikitas F; Shukla U; Knott C; Hunger M; Pahwa A; Schade R
Int J Gynecol Cancer; 2023 Nov; 33(11):1715-1723. PubMed ID: 37620100
[TBL] [Abstract][Full Text] [Related]
7. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
Future Oncol; 2021 Oct; 17(29):3781-3785. PubMed ID: 34427115
[TBL] [Abstract][Full Text] [Related]
8. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
[TBL] [Abstract][Full Text] [Related]
9. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
Rodrigues M; Eberst L; Follana P; Gauthier L; Jacquemin V; Tessier C; El Mouaddin N; Boudier P; Fiteni F; Angeli E; Roche S; Delanoy N; Sabatier R; Flippot R; de la Motte Rouge T
Bull Cancer; 2023 Oct; 110(10):1041-1050. PubMed ID: 37659907
[TBL] [Abstract][Full Text] [Related]
10. An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer.
Mathews C; Lorusso D; Coleman RL; Boklage S; Garside J
Oncologist; 2022 Dec; 27(12):1058-1066. PubMed ID: 36124638
[TBL] [Abstract][Full Text] [Related]
11. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Amonkar M; Yao L; Jin F; Norwood K; Maio M
Gynecol Oncol; 2022 Aug; 166(2):245-253. PubMed ID: 35835611
[TBL] [Abstract][Full Text] [Related]
13. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA;
N Engl J Med; 2023 Jun; 388(23):2145-2158. PubMed ID: 36972026
[TBL] [Abstract][Full Text] [Related]
14. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Oaknin A; Pothuri B; Gilbert L; Sabatier R; Brown J; Ghamande S; Mathews C; O'Malley DM; Kristeleit R; Boni V; Gravina A; Banerjee S; Miller R; Pikiel J; Mirza MR; Dewal N; Antony G; Dong Y; Zografos E; Veneris J; Tinker AV
Clin Cancer Res; 2023 Nov; 29(22):4564-4574. PubMed ID: 37363992
[TBL] [Abstract][Full Text] [Related]
15. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
[TBL] [Abstract][Full Text] [Related]
16. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
Cercek A; Lumish M; Sinopoli J; Weiss J; Shia J; Lamendola-Essel M; El Dika IH; Segal N; Shcherba M; Sugarman R; Stadler Z; Yaeger R; Smith JJ; Rousseau B; Argiles G; Patel M; Desai A; Saltz LB; Widmar M; Iyer K; Zhang J; Gianino N; Crane C; Romesser PB; Pappou EP; Paty P; Garcia-Aguilar J; Gonen M; Gollub M; Weiser MR; Schalper KA; Diaz LA
N Engl J Med; 2022 Jun; 386(25):2363-2376. PubMed ID: 35660797
[TBL] [Abstract][Full Text] [Related]
17. Dostarlimab for the treatment of advanced endometrial cancer.
Redondo A; Gallego A; Mendiola M
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):1-9. PubMed ID: 35184615
[TBL] [Abstract][Full Text] [Related]
18. The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer.
Ducceschi M; Polignano M; Bini M; Lopez S; Conca E; Tamborini E; Perrone F; Carlo Stella G; Petrella MC; Carciotto R; Artioli G; Maffeis V; Sartor L; Raspagliesi F; Mantiero M
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685607
[TBL] [Abstract][Full Text] [Related]
19. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Kasherman L; Ahrari S; Lheureux S
Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
